Cytek Biosciences, Inc. (CTKB)
NASDAQ · Healthcare
Cytek Biosciences, Inc. EBITDA 2020–2025
Cytek Biosciences, Inc. annual/quarterly ebitda history and growth rate from 2020 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Cytek Biosciences, Inc. ebitda for the quarter ending March 31, 2026 was -16.6 M, a 26.70% increase year-over-year.
- Cytek Biosciences, Inc. ebitda for the twelve months ending March 31, 2026 was -49.9 M.
- Cytek Biosciences, Inc. annual ebitda for 2025 was -32.8 M, a 146.45% increase from 2024.
- Cytek Biosciences, Inc. annual ebitda for 2024 was -13.3 M, a 38.93% decrease from 2023.
- Cytek Biosciences, Inc. annual ebitda for 2023 was -21.8 M, a 3268.17% decrease from 2022.
- Cytek Biosciences, Inc. annual ebitda for 2022 was 688000.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Cytek Biosciences, Inc. EBITDA — FAQ
Cytek Biosciences, Inc. (CTKB) ebitda over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CTKB's ebitda history?
The chart and table above show Cytek Biosciences, Inc.'s ebitda by year and by quarter, including the growth rate.